𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site

✍ Scribed by C. S. Karapetis; D. Yip; K. Virik; A. Strickland; K. Ryder; M. Cowling; P. G. Harper

Book ID
111640813
Publisher
Springer US
Year
2001
Tongue
English
Weight
83 KB
Volume
18
Category
Article
ISSN
1357-0560

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized Phase III trial of etoposid
A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma
✍ Fikri Δ°Γ§li; Δ°smail Γ‡elik; Faruk Aykan; AytuΗ§ Üner; Ahmet Demirkazik; Ahmet Γ–zet; πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 2 views

## BACKGROUND. Gastric carcinoma is a substantial health problem in Turkey, and the majority of patients present with inoperable disease. The aim of this randomized trial was to assess the activity of 5-fluorouracil versus etoposide when combined with epirubicin plus cisplatin in patients with adv

Cisplatin and gemcitabine with either vi
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : Results of an Italian Multicenter, randomized, phase II study
✍ Sergio Palmeri; Vito Lorusso; Laura Palmeri; Marina Vaglica; Camillo Porta; Rola πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 153 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established. ## METHODS. In this randomized Phase II study, 66 previously untreated patients (33 patients per arm) with carcinomas of unknown primary site received cisp